Low BMI is associated with tumor progression in patients with HR+/HER– metastatic breast cancer being treated with CDK4/6 ...
“After treatment with enzalutamide, PSA levels decline due to potent androgen receptor blockade and cell death,” Armstrong ...
Northwestern Medicine scientists have discovered that a specific long non-coding RNA activates oncogenic signaling pathways ...
Prostate cancer begins in the prostate, a small gland located just below the bladder, present only in people assigned male at birth (AMAB). This gland is in charge of producing seminal fluid, and it ...
HRD-positive tumors derived the largest median PFS gain with rucaparib maintenance versus placebo, consistent with PARP ...
When you have HR+/HER2– metastatic breast cancer, a big part of treatment includes monitoring the condition with routine scans, physical exams, and blood tests. But the type of testing you’ll need — ...
In this segment, Dr. Gregory Vidal discusses the role of estrogen receptor antagonists in the treatment of ER-positive, ...
April 2 (Reuters) - AstraZeneca said on Thursday that a combination treatment with its cancer drug Imfinzi showed significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results